Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Atrium Therapeutics, Inc. manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, suggesting a breadth of technical subject matter even within a small portfolio. The involvement of 2 distinct examiners further reflects this distribution of work across different specialized groups at the patent office.
VIVLEMORE, TRACY ANN is the busiest examiner, holding 1 busiest examiner pending action. Since the 2 pending actions are split between different examiners, the company must navigate multiple sets of examiner expectations. This diversity in the prosecution profile suggests a broader range of technical subject matter than entities with a single pending action.
For practitioners, this distribution implies that prosecution outcomes will depend on the specific standards and interpretations of multiple individuals rather than a single point of contact. Navigating this portfolio requires a versatile approach to addressing office actions from different examiners. The decentralized nature of the docket reduces the risk associated with any single examiner's tendencies affecting the entire portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16718092 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | CANELLA, KAREN A | 118d overdue |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16960543 | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF | VIVLEMORE, TRACY ANN | 1638 | §112Other | Non-Final OA | 21d | Pending | Jul 07, 2020 |
| 16718092 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | CANELLA, KAREN A | 1643 | §103 | Final Rejection | 118d overdue | Pending | Dec 17, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial